Heart failure in the elderly: Advances and challenges

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 5, 2010, Pages 695-715

  Jugdutt, Bodh I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Elderly; Heart failure low ejection fraction; Heart failure preserved ejection fraction; Therapy

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; BUCINDOLOL; BUMETANIDE; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; HYDRALAZINE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; METOPROLOL SUCCINATE; NEBIVOLOL; NESERITIDE; NITRATE; OMAPATRILAT; OXIPURINOL; PERINDOPRIL; PLACEBO; TORASEMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ADD ON THERAPY; AGED; AGING; ANGIONEUROTIC EDEMA; BRADYCARDIA; COMORBIDITY; COUGHING; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLUID RETENTION; HEALTH CARE COST; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPOTENSION; LOW DRUG DOSE; MORBIDITY; MORTALITY; POLYPHARMACY; PREVALENCE; REVIEW; SIDE EFFECT; SYSTOLIC DYSFUNCTION;

AGED; AGED, 80 AND OVER; HEART FAILURE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREVALENCE;

EID: 77952142435     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.36     Document Type: Review

References (130)

1. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 121, e1-e170 (2010).
2. Alexander KP, Newby LK, Armstrong PW et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 115, 2570-2589 (2007).
3. Jugdutt BI. Aging and remodeling during healing of the wounded heart: current therapies and novel drug targets. Curr. Drug Targets 9, 325-344 (2008).
4. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation 112, e154-e235 (2005).
5. Jessup M, Abraham WT, Casey DE et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14), 1977-2016 (2009).
6. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur. J. Heart Fail. 10, 933-989 (2008).
7. Fox KF, Cowie MR, Wood DA et al. Coronary artery disease as the cause of incident heart failure in the population. Eur. Heart J. 22, 228-236 (2001).
8. St John Sutton M, Pfeffer MA, Moye L et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 96, 3294-3299 (1997).
9. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 83, 596-602 (2000).
10. Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries: a review of the literature. Int. J. Cardiol. 80, 213-219 (2001).
11. Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106, 3068-3072 (2002).
12. Johansen H, Strauss B, Arnold JMO, Moe G, Liu P. On the rise: the current and projected future burden of congestive heart failure hospitalization in Canada. Can. J. Cardiol. 19, 430-435 (2003).
13. Wellenius GA, Mittleman MA. Disparities in myocardial infarction case fatality rates among the elderly: the 20-year Medicare experience. Am. Heart J. 156, 483-490 (2008).
14. Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J. Am. Coll. Cardiol. 53, 13-20 (2009).
15. Krumholz HM, Wang Y, Chen J et al. Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA 302, 767-773 (2009).
16. Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur. Heart J. 27, 779-788 (2006).
17. Goldenberg I, Matetzky S, Halkin A et al. Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction. Am. Heart J. 145, 862-867 (2003).
18. de Boer MJ, Ottervanger JP, van't Hof AW, Hoorntje JC, Suryapranata H, Zijlstra F. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J. Am. Coll. Cardiol. 39, 1723-1728 (2002).
19. Bolognese L, Neskovic AN, Parodi G et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 106, 2351-2357 (2002).
20. Alexander KP, Newby LK, Cannon CP et al. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 115, 2549-2569 (2007).
21. Cheitlin MD, Gerstenblith G, Hazzard WR et al. Database Conference January 27-30, 2000, Washington D.C. Do existing databases answer clinical questions about geriatric cardiovascular disease and stroke? Am. J. Geriatr. Cardiol. 10, 207-223 (2001).
22. Liu P, Arnold JMO, Belenkie I et al. The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure. Can. J. Cardiol. 17(Suppl. E), 5E-25E (2001).
23. Cheitlin MD, Zipes DP. Cardiovascular disease in the elderly. In: Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine (Volume 2). Zipes DP, Libby P (Eds). Saunders Elsevier, PA, USA, 2019-2037 (2001).
24. Schwartz JB, Zipes DP. Cardiovascular disease in the elderly. In: Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine (Volume 2). Libby P, Bonow RO, Mann DL, Zipes DP (Eds). Saunders Elsevier, PA, USA, 1923-1953 (2008).
25. McCullough PA, Khandelwal AK, McKinnon JE et al. Outcomes and prognostic factors of systolic as compared with diastolic heart failure in urban America. Congest. Heart Fail. 11, 6-11 (2005).
26. McDonald K. Diastolic heart failure in the elderly: underlying mechanisms and clinical relevance. Int. J. Cardiol. 125, 197-202 (2008).
27. Mann DL. Management of heart failure patients with reduced ejection fraction. In: Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine (Volume 1). Libby P, Bonow RO, Mann DL, Zipes DP (Eds). Saunders Elsevier, PA, USA, 611-640 (2008).
28. Pfeffer MA, Braunwald E. Ventricular remodelling after myocardial infarction. Circulation 81, 1161-1172 (1990).
29. Bujak M, Kweon HJ, Chatila K et al. Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction. J. Am. Coll. Cardiol. 51, 1384-1392 (2008).
30. Jugdutt BI. Valsartan in the treatment of heart attack survivors. Vasc. Health Risk Manag. 2, 125-138 (2006).
31. Hare JM, Mangal B, Brown J et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J. Am. Coll. Cardiol. 51, 2301-2309 (2008).
32. Packer M, Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106, 920-926 (2002).
33. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293, 1900-1905 (2005).
34. Packer M, McMurray J, Massie BM et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J. Card. Fail. 11, 12-20 (2005).
35. Kaluski E, Cotter G, Leitman M et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension - a multi-center randomized study. Cardiology 109, 273-280 (2008).
36. Kass DA, Shapiro EP, Kawaguchi M et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104, 1464-1470 (2001).
37. Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 64, 459-470 (2004).
38. Jugdutt BI, Palaniyappan A, Uwiera RRE, Idikio H. Role of healing-specific-matricellular proteins and matrix metalloproteinases in age-related enhanced early remodeling after reperfused STEMI in dogs. Mol. Cell. Biochem. 322, 25-36 (2009).
39. Heiat A, Gross CP, Krumholz HM. Representation of elderly, women and minorities in heart failure clinical trials. Arch. Intern. Med. 162, 1682-1688 (2002).
40. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316, 1429-1435 (1987).
41. Giles TD, Katz R, Sullivan JM et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J. Am. Coll. Cardiol. 13, 1240-1247 (1989).
42. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991).
43. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327, 685-691 (1992).
44. Ryden L, Armstrong PW, Cleland JG et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur. Heart J. 21, 1967-1978 (2000).
45. Cleland JG, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J. 27, 2338-2345 (2006).
46. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349, 747-752 (1997).
47. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355, 1582-1587 (2000).
48. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 100, 1056-1064 (1999).
49. Cohn JN, Tognoni G. A randomized trial of angiotensin receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001).
50. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362, 759-766 (2003). (Pubitemid 37093915)
51. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added Trial. Lancet 362, 767-771 (2003). (Pubitemid 37093916)
52. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative Trial. Lancet 362, 772-776 (2003). (Pubitemid 37093917)
53. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362, 777-781 (2003).
54. White HD, Aylward PE, Huang Z et al. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 112, 3391-3399 (2005).
55. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 359, 2456-2467 (2008).
56. Cardiac Insufficiency Bisoprolol Study (CIBIS) Investigators and Committees. A randomized trial of b-blockade in heart failure. Circulation 90, 1765-1773 (1994).
57. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334, 1349-1355 (1996). (Pubitemid 26152713)
58. No authors listed. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349, 375-380 (1997).
59. No authors listed. The Cardiac Insufficiency Bisoprolol Study II (CIBISII): a randomised trial. Lancet 353, 9-13 (1999).
60. Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA 283, 1295-1302 (2000).
61. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651-1658 (2001). (Pubitemid 32479962)
62. Beta-Blocker Evaluation of Survival Trial (BEST) Investigators. A trial of the b-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 344, 1659-1667 (2001).
63. Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106, 2194-2199 (2002).
64. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 362, 7-13 (2003).
65. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 26, 215-225 (2005).
66. Ghio S, Magrini G, Serio A et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur. Heart J. 27, 562-568 (2006).
67. Dobre D, van Veldhuisen DJ, Goulder MA, Krum H, Willenheimer R. Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial. Cardiovasc. Drugs Ther. 22, 399-405 (2008).
68. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709-717 (1999).
69. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102, 2700-2706 (2000).
70. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003).
71. Pitt B, White H, Nicolau J et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J. Am. Coll. Cardiol. 46, 425-431 (2005). (Pubitemid 41040281)
72. Mak GJ, Ledwidge MT, Watson CJ et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J. Am. Coll. Cardiol. 54, 1674-1682 (2009).
73. Packer M, Gheorghiade M, Young JB et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting-enzyme inhibitors. N. Engl. J. Med. 329, 1-7 (1993). (Pubitemid 23182871)
74. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 336, 525-533 (1997).
75. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. 314, 1547-1552 (1986).
76. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325, 303-310 (1991).
77. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J. Card. Fail. 5, 178-187 (1999).
78. Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351, 2049-2057 (2004).
79. Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N. Engl. J. Med. 343, 246-253 (2000).
80. Publication Committee for the VMAC Investigators. Intravenous Nesiritide Vs Nitroglycerin for Treatment of Decompensated Congestive Heart Failure: a randomized controlled trial. JAMA 287, 1531-1540 (2002).
81. Peacock WF 4th, Holland R, Gyarmathy R et al. Observation unit treatment of heart failure with nesiritide: results from the PROACTION trial. J. Emerg. Med. 29, 243-252 (2005).
82. Garg R, Yusuf S. Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273, 1450-1456 (1995).
83. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N. Engl. J. Med. 327, 678-684 (1992).
84. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342, 821-828 (1993).
85. ACE inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 97, 2202-2212 (1998).
86. Warner KK, Visconti JA, Tschampel MM. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angiodema. Ann. Pharmacother. 34, 526-528 (2000).
87. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch. Intern. Med. 164, 910-913 (2004).
88. Dulin BR, Haas SJ, Abraham WT, Krum H. Do elderly systolic heart failure patients benefit from b-blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Am. J. Cardiol. 95, 896-898 (2005).
89. Kramer JM, Curtis LH, Dupree CS et al. Comparative effectiveness of b-blockers in elderly patients with heart failure. Arch. Intern. Med. 168, 2422-2428 (2008).
90. Adams KF Jr, Gheorghiade M, Uretsky BF et al. Clinical benefits of low serum digoxin concentrations in heart failure. J. Am. Coll. Cardiol. 39, 946-953 (2002).
91. Rathore SS, Curtis JP, Wang Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289, 871-878 (2003). (Pubitemid 37430346)
92. Komajda M, Hanon O, Hochadel M et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur. Heart J. 30, 478-486 (2009).
93. Sin DD, McAlister FA. The effects of b-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am. J. Med. 113, 650-656 (2002).
94. Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. 355, 260-269 (2006).
95. Abhayaratna WP, Marwick TH, Smith WT, Becker NG. Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart 92, 1259-1264 (2006).
96. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 355, 251-259 (2006).
97. Yancy CW, Lopatin M, Stevenson LW et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J. Am. Coll. Cardiol. 47, 76-84 (2006).
98. Fonarow GC, Stough WG, Abraham WT et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J. Am. Coll. Cardiol. 50, 768-777 (2007).
99. Paulus WJ, Tschöpe C, Sanderson JE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J. 28, 2539-2550 (2007).
100. Redfield MM. Heart failure with normal ejection fraction. In: Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine (Volume 1). Libby P, Bonow RO, Mann DL, Zipes DP (Eds). Saunders Elsevier, PA, USA, 641-664 (2008).
101. Masoudi FA, Havranek EP, Smith G et al. Gender, age, and heart failure with preserved left ventricular systolic function. J. Am. Coll. Cardiol. 41, 217-223 (2003). (Pubitemid 36092188)
102. Ahmed A, Rich MW, Fleg JL et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 114, 397-403 (2006). (Pubitemid 44264821)
103. Tehrani F, Phan A, Chien CV, Morrissey RP, Rafique AM, Schwarz ER. Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction. Am. J. Cardiol. 103, 829-833 (2009).
104. Orn S, Dickstein K. How do heart failure patients dies? Eur. J. Heart Fail. Suppl. 4, D59-D65 (2002).
105. Mozaffarian D, Anker SD, Anand I et al. Prediction of mode of death in heart failure: the Seattle heart failure model. Circulation 116, 392-398 (2007).
106. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225-237 (2005).
107. Kadish A, Dyer A, Daubert JP et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N. Engl. J. Med. 350, 2151-2158 (2004).
108. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346, 877-883 (2002).
109. Mark DB, Nelson CL, Anstrom KJ et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 114, 135-142 (2006).
110. Jugdutt BI. Current and novel cardiac support therapies. Curr. Heart Fail. Rep. 6, 19-27 (2009).
111. Abraham WT, Fisher WG, Smith AL et al. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N. Engl. J. Med. 346, 1845-1853 (2002).
112. McAlister FA, Ezekowitz J, Hooton N et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 297, 2502-2514 (2007). (Pubitemid 46953404)
113. Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity in heart faiure. N. Engl. J. Med. 352, 1539-1549 (2005).
114. Young JB, Abraham WT, Smith AL et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 289, 2685-2694 (2003).
115. St John Sutton MG, Plappert T, Abraham WT et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 107(15), 1985-1990 (2003).
116. St John Sutton M, Ghio S, Plappert T et al. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation 120(19), 1858-1865 (2009).
117. Jones RH, Velazquez EJ, Michler RE et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N. Engl. J. Med. 360, 1705-1717 (2009).
118. Di Sciascio G, Patti G, D'Ambrosio A, Nusca A. Coronary stenting in patients with depressed left ventricular function: acute and long-term results in a selected population. Catheter. Cardiovasc. Interv. 59, 429-433 (2003).
119. Beanlands RS, Nichol G, Huszti E et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J. Am. Coll. Cardiol. 50, 2002-2012 (2007).
120. Athanasuleas CL, Buckberg GD, Stanley AW et al. Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J. Am. Coll. Cardiol. 44, 1439-1445 (2004).
121. Stevenson LW, Miller LW, Desvigne-Nickens P et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 110, 975-981 (2004).
122. Costanzo MR, Guglin ME, Saltzberg MT et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. 49, 675-683 (2007).
123. Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114, e257-e354 (2006). (Pubitemid 44252297)
124. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am. J. Cardiol. 91, 2D-8D (2003).
125. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 101, 1138-1144 (2000).
126. Boos CJ, Carlsson J, More RS. Rate or rhythm control in persistent atrial fibrillation. QJM 96, 881-892 (2003). (Pubitemid 37547897)
127. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347, 1825-1833 (2002).
128. Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med. 358, 2667-2677 (2008).
129. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J. Am. Coll. Cardiol. 54, 1089-1095 (2009).
130. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl.), 338S-400S (2004).